Home
Online Advanced Release
Current Issue
Online-only Articles
Back Issues
Product News
About the Journal
Advertising Info
Contact Us
Article Reprints
Article Submission
Buy a Book
Terms and Conditions
Careers at SLACK Inc.
ISIE
 
  e-contents - sign up today
  Subscribe to this Journal
Get daily Ophthalmic news at the OSN SuperSite

Schuman, Everyday OCT

Imaging Clinical Science

Choroidal Metastases Fundus Autofluorescence Imaging: Correlation to Clinical, OCT, and Fluorescein Angiographic Findings

Ophthalmic Surgery, Lasers and Imaging   Vol. 41   No. 4   July/August 2010
See the Full text
Sribhargava Natesh, MD; Kimberly J. Chin, OD and Paul T. Finger, MD

Share/Save/Bookmark

 

BACKGROUND AND OBJECTIVE

To correlate fundus autofluorescence (FAF) characteristics of metastatic choroidal tumors with optical coherence tomography/scanning laser ophthalmoscope (OCT/SLO).

PATIENTS AND METHODS

A retrospective review of 10 choroidal metastases in 9 patients.

RESULTS

All tumors were amelanotic, although 8 exhibited surface pigmentation. FAF imaging revealed hyperautofluorescence in areas of focal pigmentation and subretinal fluid with hypoautofluorescent margins (n = 5) corresponding to OCT evidence of retinal pigment epithelial (RPE) thickening and subretinal fluid. Loss of RPE was FAF imaging hypoautofluorescent. FAF images changed with tumor growth. OCT best revealed elevation of the RPE and retina, RPE thickening and folds, and retinal detachment.

CONCLUSION

FAF imaging best defined surface characteristics and tumor margins. FAF imaging hyperautofluorescence correlated to focal hyperpigmentation, subretinal fluid, and advancing tumor edges. OCT better demonstrated intraretinal findings (atrophy, subretinal fluid, and increased and lost RPE). This study shows that FAF imaging and OCT reveal unique tumor characteristics of choroidal metastasis.

[Ophthalmic Surg Lasers Imaging 2010;41:406-412.]

AUTHORS

From The New York Eye Cancer Center, New York, New York.

Originally submitted February 5, 2009. Accepted for publication January 13, 2010. Posted online April 29, 2010.

Supported by The Eye Cancer Foundation, Inc. (http://eyecancerfoundation.net), New York, New York, and an OCT/SLO Imaging Grant from John and Myrna Daniels (Toronto, New York, and Palm Beach).

Dr. Sribhargava Natesh was supported by a Fellowship Grant from the International Federation of Ophthalmological Societies – International Council of Ophthalmology.

The authors have no financial or proprietary interest in the materials presented herein.

Address correspondence to Paul T. Finger, MD, The New York Eye Cancer Center, 115 East 61st Street, Suite 5B, New York, NY 10065. Phone: 212-832-8170.

doi: 10.3928/15428877-20100426-03

See the Full text